PathAI
AI-driven pathology for enhanced patient outcomes.
Acquired PathAI
Acquired · May 2026
Still operating. PathAI, the Boston company building AI for pathology and the AISight image management system, signed a definitive merger agreement on May 7, 2026 to be acquired by Roche for $750 million upfront plus up to $300 million in milestones. It is to join Roche Diagnostics once the deal closes, expected in the second half of 2026.
Acquired by Roche.
Is PathAI shut down?
No — PathAI is still operating. Its acquisition by Roche was announced on May 7, 2026, and the product continues to ship. We list it in the ToolDirectory.AI graveyard's acquired-but-operating section and watch for post-acquisition changes.
Overview
Transforming Pathology with PathAI's AI-Powered Solutions
PathAI is at the forefront of revolutionizing pathology with its AI-powered technology, aiming to significantly improve patient outcomes. This innovative platform offers a unique blend of reliable AI technology and meaningful collaboration with biopharma, laboratories, and clinicians. PathAI's primary goal is to provide patients with access to accurate diagnoses and effective treatments, thereby advancing the field of medicine.
Deal note (May 2026): Roche entered into a definitive merger agreement on May 7, 2026 to acquire PathAI for $750 million upfront plus up to $300 million in milestone payments. PathAI will become part of Roche's Diagnostics division once the deal closes, expected in the second half of 2026, and continues to operate meanwhile.
Key Features:
- AI-Powered Pathology: Advanced AI algorithms for accurate and efficient diagnoses.
- AISight™ Digital Pathology Image Management System: A cloud-native solution for enterprise workflow in digital pathology.
- BioPharma Services: Comprehensive services for drug and diagnostic development.
- Extensive Pathologist Network: Over 450 board-certified pathologists contributing to AI training and validation.
- Precision Medicine: Utilizing AI to drive forward personalized treatment approaches.
- Research and Development Support: AI-powered tools aiding in groundbreaking medical research.
Ideal Use Case:
PathAI is ideal for biopharma companies, clinical laboratories, and healthcare providers seeking to enhance diagnostic accuracy and treatment efficacy through AI-powered pathology.
Why use PathAI:
- Improved Diagnostic Accuracy: Leveraging AI for more precise pathology results.
- Efficient Workflow Management: AISight™ streamlines digital pathology processes.
- Collaborative Research: Facilitating partnerships with top biopharma companies.
- Enhanced Patient Outcomes: Focused on delivering effective treatment solutions.
tl;dr:
PathAI is revolutionizing the field of pathology with its AI-driven platform, enhancing diagnostic accuracy and patient treatment outcomes. It's an essential tool for healthcare providers and researchers dedicated to advancing precision medicine.
FAQ
Is Roche acquiring PathAI? Yes. Roche agreed on May 7, 2026 to acquire PathAI for up to $1.05 billion. Once the deal closes PathAI will be part of Roche Diagnostics; until then it operates as before.
Q: What is PathAI used for? A: AI-driven pathology for enhanced patient outcomes.
Q: What is PathAI's pricing? A: Pricing varies by plan. Visit the PathAI pricing page for current tiers and details.
Q: What is PathAI's main use case? A: PathAI helps clinicians and healthcare ops teams improve diagnosis, automate documentation, and streamline patient workflows.
Q: What can replace PathAI? A: Top alternatives to PathAI include Abridge, Flatiron Health, and Exscientia. Browse the directory for full feature comparisons across these tools.
Related
Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. PathAI is also tracked on Crunchbase.
Why Use PathAI
